☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
astellas
Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients
August 27, 2024
Astellas Collaborates with Poseida Therapeutics to Develop New Allogeneic Cell Therapies in Oncology
May 2, 2024
EMA Granted Extended Approval to Astellas’ XTANDI (Enzalutamide) for Recurrent Early Prostate Cancer Treatment
April 24, 2024
Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer
March 29, 2024
Astellas Commences the P-III Evaluation of Fezolinetant for the Treatment of VMS Associated with Menopause in Japan
March 4, 2024
Astellas Reports the Submission of sNDA to the Japan MHLW for Padcev in Combination with Keytruda to Treat Advanced Bladder Cancer
January 31, 2024
Load more...
Back to Home